ArticleJournal of personalized medicine2021
Rifaximin as a Potential Treatment for IgA Nephropathy in a Humanized Mice Model.
Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Refractory IgA Nephropathy: A Challenge for Future Nephrologists.Medicina (Kaunas, Lithuania) · 2024Pooled it
- Interconnection between gut microbial metabolites and mitochondrial ROS production: implications for cellular health.Molecular and cellular biochemistry · 2026Review
- Microbiota-Gut-Kidney Axis and Targeted Therapeutic Strategies in Kidney Diseases.International journal of biological sciences · 2026Review
- Gut microbiota as a predictive tool for outcomes in IgA nephropathy.Renal failure · 2025Article
- Gut Microbiota and Immunoglobulin A Nephropathy: Exploration of Dietary Intervention and Treatment Strategies.Food science & nutrition · 2025Review
- Prognostic Value of Urinary Biomarkers in Proteinuria Progression in IgA Nephropathy Patients Treated with Budesonide.Medicina (Kaunas, Lithuania) · 2025Article
- The evolving understanding of systemic mechanisms in organ-specific IgA nephropathy: a focus on gut-kidney crosstalk.Theranostics · 2025Review
- Characteristics, pathogenic and therapeutic role of gut microbiota in immunoglobulin A nephropathy.Frontiers in immunology · 2025Review
- The pathogenesis of IgA nephropathy and implications for treatment.Nature reviews. Nephrology · 2025Review
- IgA Vasculitis (Henoch-Schönlein Purpura): An Update on Treatment.Journal of clinical medicine · 2024Review
- IgA nephropathy: gut microbiome regulates the production of hypoglycosilated IgA1 via the TLR4 signaling pathway.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Article
- Intestinal epithelium dysfunctions cause IgA deposition in the kidney glomeruli of intestine-specific Ap1m2-deficient mice.EBioMedicine · 2024Article
- Advancements in understanding the role of intestinal dysbacteriosis mediated mucosal immunity in IgA nephropathy.BMC nephrology · 2024Review
- IgA nephropathy.Nature reviews. Disease primers · 2023Review
- IgA Nephropathy: Current Understanding and Perspectives on Pathogenesis and Targeted Treatment.Diagnostics (Basel, Switzerland) · 2023Review
- The Microbiome Revolution: New Insights for Personalized Medicine.Journal of personalized medicine · 2022Article
- Is There a Role for Gut Microbiome Dysbiosis in IgA Nephropathy?Microorganisms · 2022Review
- Gut-kidney axis in IgA nephropathy: Role on mesangial cell metabolism and inflammation.Frontiers in cell and developmental biology · 2022Review
- Gut Microbes in Immunoglobulin A Nephropathy and Their Potential Therapeutic Applications.Frontiers in medicine · 2022Review
- Are there animal models of IgA nephropathy?Seminars in immunopathology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
IgA Nephropathy (IgAN) is the most common glomerulonephritis worldwide, characterized by the mesangial deposition of abnormally glycosylated IgA1 (Gd-IgA). The production of Gd-IgA occurs in mucose-associated lymphoid tissue (MALT). The microbiota plays a role in MALT modulation. Rifaximin (NORMIX
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.